^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    RBL1 (RB Transcriptional Corepressor Like 1)

    i
    Other names: RBL1, RB Transcriptional Corepressor Like 1, P107, PRB1, 107 KDa Retinoblastoma-Associated Protein, Retinoblastoma-Like Protein 1, Retinoblastoma-Like 1, Cp107, CP107, PRb1
    Associations

    News

    Trials
    4ms
    The Tumor Suppressor p53 Downregulates p107 (RBL1) Through p21-RB/E2F Signaling and Tandem E2F Sites. (PubMed, Int J Mol Sci)
    Additional experiments in RB-/- and LIN37-/- knockouts showed that RB/E2F repressing complex plays the main role in repressing the RBL1 promoter, while E2F4, p107, and p130 can support this effect to a lesser extent. Overall, our findings demonstrate that p53 controls RBL1 expression indirectly through the p21-RB-E2F pathway by utilizing two E2F binding sites within the RBL1 promoter.
    Journal
    |
    TP53 (Tumor protein P53) • CDKN1A (Cyclin-dependent kinase inhibitor 1A) • E2F1 (E2F transcription factor 1) • RBL1 (RB Transcriptional Corepressor Like 1) • RBL2 (RB Transcriptional Corepressor Like 2)
    8ms
    The tumor suppressor pRb and its relative p130 are required to maintain murine adult skeletal muscle homeostasis. (PubMed, Oncogene)
    Thus, continuous pRB and p130 expression is required to maintain skeletal muscle homeostasis and prevent adult muscle degeneration. Moreover, genetic modifiers-yet to be defined-affect the balance between muscle atrophy and regeneration.
    Preclinical • Journal
    |
    PAX7 (Paired Box 7) • RBL1 (RB Transcriptional Corepressor Like 1) • RBL2 (RB Transcriptional Corepressor Like 2)
    8ms
    Rb substantially compensates for the double loss of p130 and p107 in adult but not embryonic neural stem cell lineages. (PubMed, Cell Death Dis)
    Such deregulation is linked to opposite changes in E2F3a and E2F3b embryonic gene expressions. Our data identifies Rb as a critical pocket protein in the control and maintenance of adult OB neurogenesis, and uncovers interchangeable, dose-dependent roles for pocket proteins in the control of neuronal differentiation and survival during development.
    Preclinical • Journal
    |
    RBL1 (RB Transcriptional Corepressor Like 1) • RBL2 (RB Transcriptional Corepressor Like 2)
    8ms
    Vemurafenib Induces Senescent Phenotype with Increased Adhesion in BRAF Mutant A375 but not in Wild Type BRAF SK-MEL-2 Melanoma Cells. (PubMed, Adv Pharm Bull)
    It also strengthens the adhesive features of senescent cells, increasing their binding to fibronectin via ITGAV, which may be a part of the phenotypic mode of drug resistance or slow interaction of proliferating cancer cells with the extracellular matrix (ECM). Thus, targeting senescent cells by focal adhesion modulators may be a promising approach to control drug-resistant melanoma cells.
    Journal
    |
    BRAF (B-raf proto-oncogene) • CCND1 (Cyclin D1) • ITGA5 (Integrin Subunit Alpha 5) • ITGAV (Integrin Subunit Alpha V) • ITGB1 (Integrin Subunit Beta 1) • RBL1 (RB Transcriptional Corepressor Like 1) • ITGB3 (Integrin Subunit Beta 3)
    |
    BRAF V600E • BRAF mutation • BRAF wild-type
    |
    Zelboraf (vemurafenib)
    10ms
    Ethanol extract from Ziziphus nummularia stem inhibits MCF-7 breast cancer cell proliferation through TP53 regulating kinase (TP53RK)-mediated p53 activation: In silico and genes expression investigations. (PubMed, Narra J)
    These in silico results were confirmed by the decrease in p21 (CDKN1A) mRNA expression. In conclusion, the anti-proliferative effects of the ethanol extract from Z. nummularia stem on breast cancer cells occurred by affecting cell cycle-related genes and inhibiting apoptosis protection mediated by overexpression of p21 (CDKN1A) through p53 activity.
    Journal
    |
    TP53 (Tumor protein P53) • CCNE1 (Cyclin E1) • CDKN1A (Cyclin-dependent kinase inhibitor 1A) • E2F1 (E2F transcription factor 1) • RBL1 (RB Transcriptional Corepressor Like 1)
    10ms
    Cell cycle duration determines oncogenic transformation capacity. (PubMed, Nature)
    The shortest Tc consistently identified the cell of origin, regardless of mutation timing. Thus, relative Tc is a hallmark of initiation that distinguishes cancer-prone from cancer-resistant lineages in several settings, explaining how mutated cells escape transformation without inducing apoptosis, senescence or immune surveillance.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • RB1 (RB Transcriptional Corepressor 1) • CDK2 (Cyclin-dependent kinase 2) • CDK1 (Cyclin-dependent kinase 1) • RBL1 (RB Transcriptional Corepressor Like 1) • SKP2 (S-phase kinase-associated protein 2)
    |
    BRAF V600E • BRAF V600 • KRAS G12D • KRAS G12
    10ms
    Cryo-EM structures of PP2A:B55 with p107 and Eya3 define substrate recruitment. (PubMed, Nat Struct Mol Biol)
    Lastly, using NMR-based dephosphorylation assays, we demonstrate how B55 recruitment directs PP2A:B55 fidelity through the selective dephosphorylation of specific phosphosites. As PP2A:B55 orchestrates mitosis and DNA damage repair, these data provide a roadmap for pursuing new avenues to therapeutically target this complex by individually blocking a subset of regulators that use different B55 interaction sites.
    Journal
    |
    RBL1 (RB Transcriptional Corepressor Like 1)
    11ms
    Aurora kinase A promotes epithelial‑mesenchymal transition by regulating P130 and P107 molecules in thyroid cancer cells. (PubMed, Exp Ther Med)
    Blocking the focal adhesion kinase signaling pathway impaired the movement, migration and invasion capabilities of THCA cells, underscoring its crucial role in metastasis. In conclusion, AURKA promotes EMT by regulating P130 and P107, thereby facilitating the metastasis of THCA.
    Journal
    |
    AURKA (Aurora kinase A) • RBL1 (RB Transcriptional Corepressor Like 1) • RBL2 (RB Transcriptional Corepressor Like 2)
    12ms
    p53 regulates DREAM complex-mediated repression in a p21-independent manner. (PubMed, EMBO J)
    Re-ChIP analysis shows co-recruitment of p53 and E2F4 to known and newly identified DREAM target promoters, indicating direct repression of these targets by p53. These findings reveal a novel, transactivation-independent mechanism of p53-mediated repression, expanding our understanding of p53's tumor-suppressive functions and suggesting DREAM complex targeting as potential future avenues in cancer therapy.
    Journal
    |
    CDKN1A (Cyclin-dependent kinase inhibitor 1A) • RBL1 (RB Transcriptional Corepressor Like 1) • RBL2 (RB Transcriptional Corepressor Like 2)
    |
    TP53 mutation
    1year
    Identification of differentially expressed MiRNA clusters in cervical cancer. (PubMed, Discov Oncol)
    Our study identified MCs, their target genes, their prognostic utility, and their potential functions in CC and recommended their usefulness in CC management.
    Journal
    |
    CCNE1 (Cyclin E1) • CCND2 (Cyclin D2) • CDK2 (Cyclin-dependent kinase 2) • CCNE2 (Cyclin E2) • MIR409 (MicroRNA 409) • MIR494 (MicroRNA 494) • MIR495 (MicroRNA 495) • CDC25A (Cell Division Cycle 25A) • E2F1 (E2F transcription factor 1) • E2F2 (E2F Transcription Factor 2) • E2F3 (E2F transcription factor 3) • GNRP (Ras-Specific Guanine Nucleotide-Releasing Factor 1) • RBL1 (RB Transcriptional Corepressor Like 1) • RBL2 (RB Transcriptional Corepressor Like 2)
    over1year
    Tumor Suppressors RBL1 and PTEN are Epigenetically Silenced in IPF5 Mesenchymal Progenitor Cells by a CD44/Brg1/PRMT5 Regulatory Complex. (PubMed, Am J Physiol Lung Cell Mol Physiol)
    Our studies indicate that the CD44/Brg1/PRMT5 regulatory module not only functions to activate positive regulators of pluripotency and self-renewal, but also functions to repress tumor suppressor genes rbl1 and pten. This confers IPF MPCs with the cancer-like property of cell-autonomous self-renewal providing a molecular mechanism for relentless fibrosis progression in IPF.
    Journal
    |
    PTEN (Phosphatase and tensin homolog) • SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4) • RBL1 (RB Transcriptional Corepressor Like 1)
    |
    PTEN expression
    over1year
    A new TGF-β risk score predicts clinical and immune landscape in colorectal cancer patients. (PubMed, Ann Gastroenterol Surg)
    The feature gene TGFB2 could inhibit the efficacy of drugs such as XAV-939, Staurosporine, and Dasatinib, but promote the efficacy of drugs such as CUDC-305 and by-product of CUDC-305. Similarly, RBL1 could inhibit the drug action of Fluphenazine and Imiquimod but promote that of Irofulven. A CRC risk prognostic signature was developed on basis of TGF-β-related genes, which provides a reference for risk and further therapeutic selection of CRC patients.
    Journal • Tumor mutational burden • IO biomarker
    |
    TMB (Tumor Mutational Burden) • TGFB1 (Transforming Growth Factor Beta 1) • RBL1 (RB Transcriptional Corepressor Like 1) • TGFB2 (Transforming Growth Factor Beta 2)
    |
    dasatinib • Zyclara (imiquimod) • XAV-939 • fluphenazine • RGRN-305 • irofulven-1 (LP-100)